6th Annual Drug Discovery & Development Symposium in Paris

The meeting 

This year, the Annual Drug Discovery & Development for Pulmonary Hypertension Symposium will take place in Paris. The meeting is held annually each summer to bring leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help identify the most promising treatments for future development.

The world's best, in one place

For each meeting, we assemble a faculty with exceptional achievements and expertise, and choose topics in areas that will influence the development of therapies immediately. Each topic will be critically reviewed by an expert panel, and open dialogue will allow your voice to be heard.

Like-minded people, working towards the same goals

This Symposium serves as a unique forum:

• for stakeholders interested in treatment of pulmonary vascular diseases for the sharing of cutting-edge science with the input of international thought leaders.
• for researchers involved in the treatment of pulmonary hypertension this meeting should stimulate new ideas and approaches. 
• for the pharmaceutical and biotechnology industries that have an interest in pulmonary vascular diseases, right heart failure or orphan diseases, it is a meeting that should not be missed. 

The meeting by design allows for opportunities for interaction among colleagues during the meeting and at the evening reception.

The event will be held at Le Méridien Etoile

Each delegate will receive a private link in an email shortly after registering, with the opportunity to book at the Symposium hotel at a reduced rate. Le Méridien Etoile is located around 30 minutes from Charles de Gaulle Airport.

The date

The event will take place on 1 and 2 July 2019.

Government & regulatory registrations

If you are part of government or regulatory institution and would like to attend this event, please email admin@pvrinstitute.org and we will be in touch with registration details as fees are waived.

Trainee registrations

Trainees are permitted to register to this meeting at the discounted rate of $95.00, provided that you are able to supply documentation certifying your status as a trainee. Please follow the normal registration at the top of this page and one of our staff will be in touch with you.

Agenda

Welcome and introduction

- Updates from work streams:

• Clinical trial design
• Biomarkers
• Endpoints
• Repurposing drugs

- Summary and next steps

About the IDDI

Mission statement

To create an organisation where scientific, clinical and regulatory information and ideas can be openly shared, discussed and harmonised between pharma, academia and regulators worldwide to help bring promising new orphan drugs, early to this critical group of rare disease PH patients.

Priorities for the next 3 to 5 years are to:

• Create and facilitate a platform to allow discussion and harmonisation of ideas between Pharma, Academia and Regulators to build awareness on the disease and explore options to early diagnosis and treatment.
• Explore innovative and suitable clinical trial designs, endpoints, biomarkers and repurposing drugs opportunities for different forms of PH.
• Leverage deep phenotyping programmes at PH specialised centres to inform and enrich new clinical trial designs based on patient subsets (“Personalised Medicine”).
• Explore acceleration potential of clinical trials to bring novel orphan drugs as soon as possible to this critically ill group of PH patient.
• Include the view of patients, regulators and nurses, and their advocacy groups.